News » Health
Canada announces first commercial production of lutetium-177 for cancer treatment.
in Canada, announced the start of commercial production of lutetium-177.
This is the first of its kind to achieve a commercial power reactor with the added capability of commercial production of short-lived medical isotopes.
Last June Bruce Power announced a plan to produce lutetium-177 (Lu-177) at a commercial nuclear reactor thanks to a new isotope production system (IPS) installed during a scheduled overhaul of the Bruce-7 reactor.
However, this goal was achieved only recently, following the completion of final commissioning and regulatory approval from the Canadian Nuclear Safety Commission for a project to install a new Isotope Production System (IPS) at Bruce Power Unit 7.
Follow us on Telegram